| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P F Buckley, O Kausch, G Gardne. Clozapine treatment of schizophrenia: implications for forensic psychiatry. Journal of clinical forensic medicine. vol 2. issue 1. 2005-02-28. PMID:15335661. |
clozapine, a new antipsychotic medication, is now the first-line treatment for neuroleptic refractory schizophrenia. |
2005-02-28 |
2023-08-12 |
Not clear |
| A Elif Anil Yağcioğlu, Berna B Kivircik Akdede, Tolga I Turgut, Mevhibe Tümüklü, M Kâzim Yazici, Köksal Alptekin, Aygün Ertuğrul, Karu Jayathilake, Ahmet Göğüş, Zeliha Tunca, Herbert Y Meltze. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. The Journal of clinical psychiatry. vol 66. issue 1. 2005-02-24. PMID:15669890. |
the purpose of this study was to carry out a placebo-controlled, randomized, double-blind trial of the efficacy, safety, and tolerability of adjunctive treatment with risperidone in patients with schizophrenia partially responsive to clozapine. |
2005-02-24 |
2023-08-12 |
Not clear |
| Richard C Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood Dadvand, Wynn Wynn Paing, Rita A Shaughness. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. The American journal of psychiatry. vol 162. issue 1. 2005-02-18. PMID:15625211. |
clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. |
2005-02-18 |
2023-08-12 |
Not clear |
| Richard C Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood Dadvand, Wynn Wynn Paing, Rita A Shaughness. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. The American journal of psychiatry. vol 162. issue 1. 2005-02-18. PMID:15625211. |
the authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia. |
2005-02-18 |
2023-08-12 |
Not clear |
| Sudeep S Gil. Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia. Evidence-based mental health. vol 8. issue 1. 2005-02-10. PMID:15671515. |
stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia. |
2005-02-10 |
2023-08-12 |
Not clear |
| Alan I Green, David T Chau, Wing Ming Keung, Ree Dawson, Raquelle I Mesholam, Joseph J Schildkrau. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry research. vol 128. issue 1. 2005-02-08. PMID:15450910. |
the results are compatible with the observations that clozapine, but not haloperidol, limits alcohol use in patients with schizophrenia. |
2005-02-08 |
2023-08-12 |
Not clear |
| Aileen O'Brie. Starting clozapine in the community: a UK perspective. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521789. |
clozapine is the most effective antipsychotic available for the treatment of schizophrenia that has proved resistant to other medications and the only antipsychotic licensed for this indication. |
2005-02-04 |
2023-08-12 |
Not clear |
| Paz Toren, Sharon Ratner, Nathaniel Laor, Abraham Weizma. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug safety. vol 27. issue 14. 2005-01-24. PMID:15554747. |
the purpose of this review is to assess the published data on the use of atypical antipsychotics in children and adolescents with schizophrenia alone and with comorbid disorders, and to establish benefit-risk guidelines for clinicians.risperidone, olanzapine and clozapine were found to be effective in the treatment of aggression and mania. |
2005-01-24 |
2023-08-12 |
Not clear |
| Larry Alphs, Ravi Anand, M Zahur Islam, Herbert Y Meltzer, John M Kane, Ranga Krishnan, Alan I Green, Steven Potkin, Guy Chouinard, Jean-Pierre Lindenmayer, Rob Kerwi. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophrenia bulletin. vol 30. issue 3. 2005-01-24. PMID:15631247. |
the international suicide prevention trial (intersept): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. |
2005-01-24 |
2023-08-12 |
Not clear |
| Isaac Sakinofsky, Hannele Heila, Ranga Krishna. Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. Schizophrenia bulletin. vol 30. issue 3. 2005-01-24. PMID:15631248. |
the intersept study compared clozapine and olanzapine prospectively, on reduction of suicidality in schizophrenia and schizoaffective disorder. |
2005-01-24 |
2023-08-12 |
Not clear |
| J Munro, P Matthiasson, S Osborne, M Travis, S Purcell, A M Cobb, M Launer, M D Beer, R Kerwi. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta psychiatrica Scandinavica. vol 110. issue 4. 2005-01-11. PMID:15352931. |
amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. |
2005-01-11 |
2023-08-12 |
Not clear |
| J Munro, P Matthiasson, S Osborne, M Travis, S Purcell, A M Cobb, M Launer, M D Beer, R Kerwi. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta psychiatrica Scandinavica. vol 110. issue 4. 2005-01-11. PMID:15352931. |
treatment options are very limited for individuals with schizophrenia resistant to clozapine. |
2005-01-11 |
2023-08-12 |
Not clear |
| Young-Chul Chung, Zhu Li, Jin Dai, Herbert Y Meltzer, Junji Ichikaw. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain research. vol 1023. issue 1. 2004-12-21. PMID:15364019. |
atypical antipsychotic drugs (apds) such as clozapine, but not the typical apd haloperidol, improve some aspects of cognition in schizophrenia. |
2004-12-21 |
2023-08-12 |
rat |
| Young-Chul Chung, Zhu Li, Jin Dai, Herbert Y Meltzer, Junji Ichikaw. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain research. vol 1023. issue 1. 2004-12-21. PMID:15364019. |
these differences may contribute, at least in part, to the superior ability of clozapine, compared to haloperidol, to improve cognition in schizophrenia. |
2004-12-21 |
2023-08-12 |
rat |
| Antonio Ciapparelli, Francesca Ducci, Claudia Carmassi, Marina Carlini, Rosemma Paggini, Mario Catena, Matteo Bottai, Liliana Dell'Oss. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. European archives of psychiatry and clinical neuroscience. vol 254. issue 5. 2004-12-20. PMID:15365711. |
this study aims at identifying potential predictors of clinical response and functional outcome in 101 neuroleptic-refractory patients with a dsm-iii-r diagnosis of schizophrenia (n = 34), schizoaffective disorder (n = 30) or bipolar disorder with psychotic features (n = 37), naturalistically treated with clozapine over a 48-month period. |
2004-12-20 |
2023-08-12 |
Not clear |
| Hubert H Fernandez, Joseph H Friedman, M Cecilia Lansang, Stewart A Factor, Eric S Molho, D Jim Cosku. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism & related disorders. vol 10. issue 7. 2004-12-20. PMID:15465403. |
there is accumulating data suggesting that clozapine may be associated with increased frequency of diabetes mellitus (dm) compared to conventional neuroleptic drugs in treating schizophrenia. |
2004-12-20 |
2023-08-12 |
human |
| Rafael Stryjer, Rael Strous, Faina Bar, Ginette Shaked, Roni Shiloh, Silvio Rozencwaig, Daniel Grupper, Nili Buchman, Moshe Kotler, J Martin Rabey, Abraham Weizma. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Human psychopharmacology. vol 19. issue 5. 2004-12-15. PMID:15252826. |
donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. |
2004-12-15 |
2023-08-12 |
Not clear |
| Rafael Stryjer, Rael Strous, Faina Bar, Ginette Shaked, Roni Shiloh, Silvio Rozencwaig, Daniel Grupper, Nili Buchman, Moshe Kotler, J Martin Rabey, Abraham Weizma. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Human psychopharmacology. vol 19. issue 5. 2004-12-15. PMID:15252826. |
although this preliminary study failed to demonstrate a clear effect of donepezil augmentation in clozapine treated chronic schizophrenia patients, it seems that the subtle positive effect of donepezil observed in some of our patients should encourage further investigation in a larger sample of this patient subpopulation. |
2004-12-15 |
2023-08-12 |
Not clear |
| C Reist, C Mazzanti, R Vu, K Fujimoto, D Goldma. Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr. Molecular psychiatry. vol 9. issue 9. 2004-12-08. PMID:15037867. |
the 5-ht(2a) his452tyr polymorphism alters signal transduction, and has been associated with diminished efficacy of clozapine in schizophrenia. |
2004-12-08 |
2023-08-12 |
human |
| M Zink, E Mase, H Dressin. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Human psychopharmacology. vol 19. issue 4. 2004-12-02. PMID:15181656. |
combination of ziprasidone and clozapine in treatment-resistant schizophrenia. |
2004-12-02 |
2023-08-12 |
Not clear |